Overview of Albumin 5%

Understanding Albumin 5%

Albumin 5% is a sterile, clear, or slightly viscous protein solution derived from human plasma. It is categorized as a colloid, a type of fluid used for volume replacement therapy. The solution contains human albumin, which is the most abundant protein found in human blood, accounting for approximately half of the total protein content in the plasma.

The Role of Albumin in the Body

Albumin is naturally produced by the liver and serves several essential functions in the circulatory system:

Maintenance of Oncotic Pressure: Albumin is the primary driver of colloid osmotic pressure. This pressure acts as a force that keeps fluid inside the blood vessels, preventing it from leaking into the surrounding tissues.
Transport and Binding: It acts as a carrier protein, binding to and transporting various substances throughout the bloodstream, including hormones, fatty acids, bilirubin, and certain minerals.

Characteristics of the 5% Concentration

The 5% concentration of albumin is considered iso-oncotic with human plasma. This means that the osmotic pressure of the solution is approximately equal to that of normal human blood. When administered intravenously, Albumin 5% increases the volume of circulating blood by an amount roughly equivalent to the volume infused.

Composition

Albumin 5% is prepared from the pooled plasma of human donors. The manufacturing process includes specific steps to isolate the albumin and inactivate potential viral agents. The final solution is stabilized to maintain the protein structure and adjusted for pH and electrolyte balance to be compatible with human administration. It does not contain clotting factors or other blood cells.

Regulatory References

NIH, Physiology, Albumin

What side effects are possible with Albumin 5%?

Possible Side Effects and Safety Information

The safety profile of Albumin 5% solution, derived from human plasma, is primarily characterized by the risk of hypersensitivity reactions and complications related to its intended effect of plasma volume expansion, as documented in regulatory labeling.

Officially Documented Adverse Reactions

Adverse reactions are officially grouped by their effect on body systems. The most clinically relevant categories involve the Immune System and Vascular Disorders.

System-Organ Class	Examples of Reactions (Based on Regulatory Labeling)
Immune System Disorders	Hypersensitivity reactions, Anaphylactic reaction, Anaphylactic shock
Vascular Disorders	Hypotension (low blood pressure), Flushing, Shock
General Disorders	Chills, Pyrexia (fever), Nausea, Vomiting

Frequency and Severity Classification

Mild reactions, such as flush, urticaria (hives), fever, and nausea, are typically classified as Rare in official documents. Severe, life-threatening reactions such as shock may be classified as Very Rare. Many reported reactions, including anaphylactic shock and tachycardia (increased heart rate), are often classified as Frequency Not Known due to being spontaneous reports from an uncertain population size.

Clinically Significant Safety Considerations

Serious adverse reactions primarily include anaphylactic shock and complications of fluid overload, such as Pulmonary Edema and Circulatory Overload. The label states that mild reactions often disappear rapidly when the infusion is slowed or stopped, while severe reactions require immediate discontinuation.

Because the solution is a plasma volume expander, caution is explicitly required in patients with pre-existing conditions that are sensitive to volume increase, such as decompensated cardiac insufficiency or severe anemia. The label also notes that when large volumes are administered, monitoring for electrolyte imbalances and hemodilution is necessary. As a product of biological origin, a theoretical, extremely remote risk of infectious agent transmission exists, though this is minimized by mandatory donor screening and pasteurization.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Albumin 5% defines an overdose as a state of hypervolaemia (circulatory overload) that occurs if the infusion's dosage or rate is not properly adjusted to the patient's existing circulatory status. This condition can lead to cardiovascular overload.

Documented Overdose Signs and Required Actions

Physiological Systems Affected	Documented Overdose Presentation
Cardiovascular System	Hypervolaemia, Cardiovascular Overload

The first clinical signs that indicate cardiovascular overload are crucial indicators for emergency action. These signs include:

Headache
Dyspnoea (shortness of breath)
Jugular vein congestion
Increased blood pressure
Raised central venous pressure
Pulmonary oedema

When Immediate Medical Help is Required

Regulatory documents explicitly instruct that the infusion must be stopped immediately when the first clinical signs of cardiovascular overload are observed. The patient's haemodynamic parameters must then be carefully monitored. Conditions where hypervolaemia poses a special risk, such as severe anaemia, decompensated cardiac insufficiency, or pulmonary oedema, require particular caution during infusion to prevent this type of overdose.

Therapeutic Uses of Albumin 5%

What Albumin 5% Treats: Main Uses and Benefits

Albumin Solution 5% is primarily applied in addressing certain distressing symptoms associated with severe and acute conditions, addressing symptoms related to systemic imbalance due to volume and protein challenges. Its use is relevant in contexts involving heightened systemic burden due to volume and protein loss.

The medication is commonly used to support patients experiencing hypovolemia (low circulating blood volume) and symptoms that create noticeable physiological strain. It is considered relevant for easing challenging symptoms of conditions resulting from protein loss, such as severe burns and acute nephrotic syndrome. Furthermore, it is applied in situations involving severe acute complications of liver cirrhosis, including managing fluid issues and may assist with maintaining functional stability following large-volume paracentesis.

In these contexts, the solution helps the body properly retain fluid within the bloodstream. This provides supportive relief when symptoms interfere with routine activities, assisting with maintaining functional stability.

Quick Fact: Support for Systemic Imbalance Symptoms
Main Conditions: Hypovolemia, Severe Burns, Nephrotic Syndrome, Liver Cirrhosis Complications
Primary Symptom Type: Symptoms related to systemic imbalance and heightened physiological activity
Use Scenario: Applied in acute clinical settings for short-term symptomatic assistance

Eligibility and Restrictions for Use

Who Can and Cannot Use Albumin 5%?

The eligibility profile for Albumin 5% is determined by government regulatory bodies and focuses on avoiding serious complications related to fluid volume overload.

Absolute Exclusions (Contraindications)

Individuals must not use this medicine if they have:

A known hypersensitivity (allergy) to human albumin preparations or to any non-active ingredients (excipients) in the specific product formulation.
Severe anemia or cardiac failure (heart failure), especially when accompanied by normal or increased fluid volume within the blood vessels.

Restricted or Conditional Use

Use of Albumin 5% requires special caution and careful monitoring in patients with conditions where volume expansion could pose a significant risk, including:

Decompensated heart failure
High blood pressure (Hypertension)
Pulmonary edema (fluid in the lungs)
Hemorrhagic diathesis (bleeding tendency)
Esophageal varices

Population Restrictions

Safety has not been established in controlled clinical trials for certain groups, and use is restricted to situations where the benefit is clearly needed and outweighs potential risks:

Pregnancy and Lactation (Breastfeeding): Use is only recommended when clearly necessary.
Pediatric Use: While clinical experience suggests children respond similarly to adults, dosage must be carefully adjusted to the child's specific requirements.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Albumin 5% solution is primarily defined by administration constraints rather than systemic drug-drug interactions. Authoritative regulatory sources confirm that no specific interactions of human albumin with other medicinal products are known regarding metabolic or transporter pathways. This means the solution does not typically alter the concentration or clearance of co-administered medicines through liver enzymes or transport proteins.

Administration Incompatibilities and Prohibitions

The administration of Albumin 5% is subject to critical incompatibility restrictions established in official prescribing information. The most significant restriction is the strict prohibition against using Sterile Water for Injection as a diluent. This mixture is a contraindicated combination because it carries a high risk of inducing hemolysis (red blood cell rupture).

Furthermore, the solution must not be mixed with other specified substances in the same infusion container or line. Official regulatory documents list protein hydrolysates, amino acid mixtures, and solutions containing alcohol (Ethanol) as incompatible. Combining the solution with these products can lead to precipitation, compromising the product's integrity.

In specific clinical settings, the product is officially documented for co-administration with Loop Diuretics, where the combination is used to formally leverage a pharmacodynamic effect that assists diuresis.

Mechanism of Action

Primary Oncotic Mechanism and Volume Expansion

The central pharmacodynamic action of Human Albumin 5% is the immediate and direct increase of the colloid osmotic pressure (COP) within the intravascular space. Albumin, being the most abundant protein in plasma, is the primary determinant of COP. As an iso-oncotic solution, infused Human Albumin 5% establishes an osmotic gradient across the capillary membrane. This gradient serves as the molecular driving force to mobilize fluid from the extravascular (interstitial) tissues back into the intravascular space. This cascading effect results in an increase in the circulating blood volume, which leads directly to an increase in cardiac pre-load and subsequently modulates hemodynamic activity.

Carrier Function and Endothelial Protection ️

Beyond its primary role, albumin acts as a non-specific carrier protein, reversibly binding to and transporting a vast array of endogenous and exogenous molecules, including bilirubin, fatty acids, thyroid hormones, and trace metals. This binding enables the distribution and metabolism of these substances. Furthermore, albumin interacts directly with the vascular endothelium, plays a role in glycocalyx protection, and exhibits antioxidant properties by scavenging free radicals. This ancillary mechanism modulates capillary permeability and contributes to the overall systemic effect produced by the volume mechanism.

Dosage and Administration Information

How to Use Albumin 5%

Albumin Solution 5% is strictly administered via Intravenous Infusion within a clinical setting. The dosage is not determined by measuring the patient's plasma albumin level; instead, the dose is titrated based on the patient's clinical response and the adequacy of their circulating fluid volume. The total dose administered must not exceed 2 g per kg of body weight.

Official Dosing and Frequency

Indication / Principle	Official Labeled Regimen
Hypovolemia (Adult Initial Dose)	25 g (500 mL of 5% solution) is administered. The dose may be repeated after 15 to 30 minutes if the circulatory response is inadequate.
Pediatric Dosing	For children under 13 years, the dose range is 0.5 to 1 g per kg of body weight.
Acute Nephrosis	Administered once a day for 7 to 10 days in conjunction with a diuretic.

Administration Rate and Preparation

The rate of infusion is procedurally governed by the patient’s condition. In non-shock cases, the standard rate is 1 to 2 mL per minute. However, for patients in severe shock, the infusion may be delivered as rapidly as the administration set allows according to official parameters.

Handling / Restriction	Labeled Instruction
Required Diluents	The solution must not be diluted with sterile water for injection due to the risk of hemolysis. Compatible diluents include 0.9% saline or 5% dextrose solution.
Usage After Opening	The solution is preservative-free and the contents must be used within four hours of opening the container.

Recent Clinical Evidence

Research Evidence for Volume Restoration (Hypovolemia and Shock)

Albumin 5% was studied for its role in supporting circulating blood volume (hypovolemia) through Randomized Controlled Trials (RCTs) and meta-analyses comparing it against other fluid solutions. Studies primarily measured parameters of circulatory function, vasopressor use, and intermediate-term survival. The findings describe patterns reported where the observed survival rates appeared similar to those of comparator fluids, though some findings indicate associations related to the duration of ventilator support in certain critically ill populations. However, the evidence is limited by patient heterogeneity, and whether consistent differences were observed in overall patient survival across all settings remains uncertain.

Research Evidence for Liver Cirrhosis Complications

High-level research was evaluated in two specific acute complications of liver cirrhosis.

Studies on Preventing Complications After Paracentesis

For Large-Volume Paracentesis (LVP), multiple RCTs examined its use following fluid removal, monitoring the development of circulatory dysfunction and renal impairment. The findings indicate that its use was associated with a lower measured rate of these complications.

Studies on Spontaneous Bacterial Peritonitis (SBP)

Similarly, as adjunctive therapy for Spontaneous Bacterial Peritonitis (SBP), studies monitored whether the treatment was associated with a reduction in complications and mortality. The research in this specific scenario is primarily supported by consistent high-level evidence (RCTs and meta-analyses).

Research Gaps and Extended Follow-up

Research was studied for use in patients with severe burn injuries and for fluid balance issues in conditions like Acute Nephrotic Syndrome, but these studies are often small-scale or show transient effects. The overall evidence base for Albumin 5% focuses on acute, disruptive episodes. Long-term effects are not fully established, as follow-up durations were limited in many core studies. While specific studies have been observed in pediatric populations, data for certain groups remain insufficient, and the available research does not determine whether an individual will respond similarly.

Key Studies & References Albumin administration in the acute phase of burn injury: a systematic review and meta-analysis.

Frequently Asked Questions (FAQ)

Common questions about Albumin 5% (FAQ)

Q: What is the main difference between Albumin 5% and Albumin 25%?

A: Albumin 5% is an iso-oncotic solution, meaning its concentration is similar to the body's natural plasma. Its primary function is to expand the blood volume by the amount infused. Albumin 25% is hyper-oncotic (more concentrated), and official documents state it creates a larger osmotic pull, causing a greater shift of fluid from the body's tissues into the bloodstream.

Q: How quickly does Albumin 5% start working after it is given?

A: As a colloid, Albumin 5% is officially described as having an immediate and direct therapeutic action on the body's circulating blood volume. The therapeutic action to increase volume is described as starting at the time of infusion. While the duration of the infusion may vary based on clinical need, the purpose is to produce a prompt volume increase.

Q: What are the most common expected feelings or reactions after an infusion?

A: Official product information suggests that mild, common reactions can include temporary feelings like flushing (a warm feeling), nausea, fever, or chills. Regulatory documents state these mild reactions often resolve rapidly when the healthcare professional slows or stops the infusion.

Q: What happens if a patient receives Albumin 5% too quickly?

A: Regulatory documents caution that rapid administration carries a risk of circulatory overload, which means too much fluid in the bloodstream too fast. This risk is greater for patients with underlying heart or blood pressure conditions. Rapid infusion has been associated with complications such as pulmonary edema (fluid in the lungs) or a significant drop in blood pressure.

Q: How do healthcare providers decide if 5% or 25% is needed?

A: Official guidance distinguishes the primary uses of the two concentrations. The 5% solution is typically used when the main goal is volume replacement, such as in hypovolemia or shock. The 25% solution is indicated for use when a higher oncotic effect is desired and the patient's fluid or sodium intake must be restricted.

Q: Can a person get an overdose of Albumin 5%?

A: Official labeling establishes a total maximum dose that should not be exceeded. Exceeding this limit carries a risk of hypervolemia (fluid overload). Official warnings state the symptoms of this overload may include shortness of breath, wheezing, and chest pain.

Q: Are there any long-term side effects linked to Albumin 5%?

A: Most documented side effects are acute reactions. Official regulatory sources do not typically list specific long-term side effects, and the evidence base often focuses on acute episodes. This suggests that the known safety risks are primarily defined by immediate and transient reactions.

Q: Is Albumin 5% considered a blood product?

A: Yes, Albumin 5% is officially classified as a Plasma Derivative or Blood Derivative. It is a sterile solution of the albumin protein that is carefully purified and isolated from donated human plasma, which means it is treated as a regulated blood product.

Q: Can Albumin 5% affect my kidney function?

A: Official warnings note that Albumin 5% requires caution in patients who have pre-existing kidney impairment due to the fluid volume increase it causes. Separately, some studies have examined the medicine’s association with improved renal blood flow in specific critically ill patient groups with kidney issues related to liver conditions.

Q: Does Albumin 5% interact with common pain medications?

A: Official drug documents state that no specific metabolic interactions with other medicinal products, including common pain relievers, are known. Regulatory documents recommend informing healthcare providers of all medications they are taking, including over-the-counter pain relievers and supplements, as part of standard administration precautions.

Q: Does Albumin 5% interact with diabetes medication?

A: Official documentation does not list specific drug-drug interactions with common diabetes medications. However, one of the stabilizers used in the manufacturing process, sodium caprylate, has been noted in certain studies for its potential to influence carbohydrate metabolism and insulin release.

Q: Can older adults use Albumin 5% safely?

A: The FDA label does not restrict use based on age, but cautions emphasize that the risk of circulatory overload and congestive heart failure is a special consideration for some populations. Official warnings note that older patients are a group for whom monitoring is especially required due to increased risks of volume-related complications.

Q: Is Albumin 5% related to immunoglobulins?

A: While Albumin and Immunoglobulins (IG) are both separate therapeutic products that are derived from human plasma, they have different functions. Albumin is primarily used for fluid balance and transport, while immunoglobulins are used to provide passive immunity (infection fighting).

Q: Does Albumin 5% have an impact on blood clotting?

A: The product is not classified as a blood thinner. However, regulatory documents emphasize that when large volumes of albumin are administered, monitoring of coagulation (clotting) levels and other blood cell counts is required as a procedural precaution.

Q: What is the difference between Albumin and whole blood or plasma?

A: Albumin 5% is a highly specific product that contains only the albumin protein purified from human plasma. Whole blood contains red cells, white cells, and all other components. Plasma contains albumin, along with clotting factors, immunoglobulins, and other proteins, which are largely removed during the process of manufacturing Albumin 5%.

Q: Is it normal to feel a change in heart rate during the infusion?

A: Official documentation lists both tachycardia (fast heart rate) and other changes in heart rate as possible reactions. Because any heart rate change can be a sign of a systemic reaction or circulatory overload, official warnings state that healthcare providers are required to monitor the heart rate closely before, during, and after administration.

Q: Does Albumin 5% contain sodium?

A: Yes, Albumin solutions contain electrolytes. Official documents confirm that some formulations of Albumin 5% are described as containing a measurable amount of sodium (for example, approximately 140 mmol/L in some common products).

Q: Is Albumin 5% a prescription medicine?

A: Yes. Regulatory records from governmental bodies, such as the FDA Verification Portal, classify Human Albumin solution for intravenous infusion as a Prescription Drug (Rx).

How should Albumin 5% be stored and disposed of?

How to Store and Dispose of Albumin 5%

Storage and disposal must strictly adhere to regulatory guidelines to maintain product integrity and safety.

Official Storage Conditions

Condition	Requirement
Temperature	Store between 2°C and 25°C (36°F and 77°F).
Freezing	Do not freeze the solution.
Protection	Keep in the original container to protect from light.
Child Safety	Store out of the sight and reach of children.

Stability and Disposal

The product is for single use only and does not contain preservatives. Administration must be completed within 4 hours after the container is entered. The solution must be visually clear; do not use if turbid or discolored. Any unused portion must be discarded in accordance with local pharmaceutical waste requirements.

Albumin 5%